• We offer tailored partnerships to support and transform drug discovery.

    Every collaboration is a bespoke arrangement, meticulously designed to discover new compounds and targets in patient relevant disease models.

  • MIMETAS offers flexible fee-for-service solutions for therapy prioritization, optimization, and de-risking of compounds.

    As an extension of your team, MIMETAS provides the expertise and resources needed for effective research and development.

  • Our OrganoReady program is made for you when you need optimized assays for investigational toxicology.

    We guarantee OrganoReady performance according to specifications, in a fast and convenient sales transaction with a clear fee structure.

  • Giving you some food for thought. Read our blogs to learn more about 3D tissue culture, research backgrounds, developments, and its future outlook.

  • Get inspired by research done by our scientists, partners, and customers around the globe.

  • Learn about our mission, vision, the history of the company, and find out what we mean with MIMETAS-do.
open menu icon close menu icon
EN

OrganoTEER®

Perform TransEpithelial/Endothelial Electrical Resistance (TEER) measurements in OrganoPlate® with this fast, automated, and impedance-based TEER device. Allowing you to assay 40-64 tissue culture chips
with a few clicks, in less than one minute.

OrganoTEER® features:

OrganoTEER Specification FlyerOur Technology

Product details

Meet the OrganoTEER


High-throughput TEER measurements
Measure 40-64 samples at once in under a minute.

Assessment of barrier function under physiological conditions
Evaluate epithelial and endothelial function under flow, without the interference of artificial membranes.

Obtain TEER values from all your samples in real-time
While leaving your cells intact and undisturbed.

Perform time-lapse measurements
Perform long-term time-lapse studies and save time for other experiments.

Supporting a range of applications in high-throughput
Suitable for research on in vitro endothelial and epithelial barrier models of gut, blood-brain-barrier, kidney, and more.

User-friendly device and software
Intuitive system, easy to maintain.




Request QuoteKeep me informed

Applications

  • Assess endothelial and epithelial barrier function of 3D tissue models at high-throughput
  • Evaluate toxicity effects of compound libraries in high-throughput

MIMETAS OrganoTEER for in-vitro 3D barrier integrity assessment

OrganoTEER Webinar

How the OrganoTEER is used in routine screens

"The OrganoPlate® 3-lane platform with the OrganoTEER will become a standardized assay in our early investigative toxicology drug screening workflow. With the OrganoPlate® we see a reproducible early screen for intestinal toxicity, and the first example internally of an advanced cell model being implemented into routine testing.

To date, the OrganoPlate Caco-2 model is for us, at Merck, the most suitable platform offering at the same time scalability, speed, robustness, ease of handling, with low compound needs."

Philip Hewitt, Early Investigative Toxicology, Pre-clinical Safety, Merck

OrganoTEER: how it works


Perform OrganoTEER® measurements
By characterizing tubular models with OrganoTEER® measurements, you can perform exposure studies to evaluate cytotoxicity and inflammatory reaction to compounds over minutes, hours, and days. You will be able to do timelapse series in the incubator and under flow conditions.

Fast data analysis
The OrganoTEER device comes with a laptop with pre-installed OrganoTEER® software. The intuitive software allows you to quickly select which chips you want to measure, give immediate results, and save you time on data analysis.

Watch the video to learn step-by-step how OrganoTEER® can be implemented in your workflow.

Want to know more?


Get up to speed with 3D tissue culture and learn how OrganoPlate® supports your research needs.

Read our Publications Contact us

Living innovation

What customers say
'
Our exciting collaboration enables our research and early development group to apply state-of-the-art organ-on-a-chip technology in the modeling of IBD and HBV. These models have the potential to improve our understanding of disease biology and transform

James Sabry, Global Head
Roche Pharma Partnering

The 'I' in MIMETAS
'
Tackling challenges together.

Linda Gijzen
Scientific Project Lead

What customers say
'
"The OrganoReady Colon Caco-2, combined with the OrganoTEER, have become our gold standard in vitro model for the screening of intestinal barrier disruptors at SIAF. "

Cezmi Akdis
Director SIAF
University Zurich

What customers say
'
The OrganoPlate Caco-2 model is for us, at Merck, the most suitable platform offering at the same time scalability, speed, robustness, ease of handling, with low compound needs.

Philip Hewitt
Head of Early Investigative Toxicology
Merck KGaA

The 'I' in MIMETAS
Chiwan Chiang
Marketing Specialist
'
A day without
laughter is a day wasted.
Read more
What customers say
'
Mimetas' tumor infiltration platform demonstrated a therapeutic effect of our compound on immune cell recruitment: we’re very excited by these proof of concept data

Scientist
From a top pharma

The 'I' in MIMETAS
Jos Joore
CEO
'
We want to
empower research on complex tissue biology.
Read more
What customers say
'
Often you have to compromise it’s either the throughput or it’s the complexity of the model. Getting both in the same platform… no other platform can do that!

Scientist
From a top pharma

The 'I' in MIMETAS
Nienke Wevers
Senior Scientist
'
Nothing ventured, nothing gained.
Read more
What customers say
'
We were able to measure cell barrier permeabilities in a lung-on-a-chip model demonstrating superior sensitivity and translatability than any other lung cell model we tried before. It was also very easy to scale up our data generation workflow.

Scientist
From a top commercial organization

The 'I' in MIMETAS
Henriëtte Lanz
Director of Model Development
'
It should be
mandatory to
socialize with colleagues.
Read more
What customers say
'
Organoplates opened avenues that were before considered unreachable

Laura Perin, PhD
Children’s Hospital Los Angeles

The 'I' in MIMETAS
Bas Trietsch
Chief Technology Officer
'
We try to help
each other
as a team.
Read more
The 'I' in MIMETAS
Jacquelien Ten Dam
Chief Financial Officer
'
It always seems impossible until it’s done.
Read more
The 'I' in MIMETAS
Paul Vulto
CEO
'
Leveraging who you are, is the key to making a difference!
Read more
The 'I' in MIMETAS
Linda Gijzen
Scientific Project Lead
'
Tackling challenges together.
Read more
The 'I' in MIMETAS
Tina Thakkar
Associate Director of Sales
'
It is not really
work if you are
having fun.
Read more
The 'I' in MIMETAS
Liis Rannamäe
Laboratory Technician
'
Can be summarized in three words - engaging, playful, and innovative.
Read more
The 'I' in MIMETAS
Mieke Doornbos
Vice President Sales & Marketing
'
Celebrate
good times.
Read more
The 'I' in MIMETAS
Frederik Schavemaker
Product Design Engineer
'
Pioneering, bringing the best solutions
for scientific
discovery.
Read more
The 'I' in Mimetas
Remko van Vught
Vice President Business Development
'
Making
a difference
together.
Read more
The 'I' in MIMETAS
Lenie van den Broek
Director Biology Discovery
'
Dynamic and innovative - each day holds a surprise.
Read more
The 'I' in Mimetas
Arnaud Nicolas
Associate Director TechCore
'
Own your flaws.
Read more
Latest Whitepaper
'
Closing the Translational Gap in Cancer Drug Discovery with Comprehensive Tumor Models

Discover insights from six oncology applications of MIMETAS’ 3D tumor models.


Download the whitepaper

New Webinar
'
Phenotypic Disease Modeling for Immuno-Oncology: Putting Targets into Patient Context


Now available on demand.

Watch it here

Press Release
'
MIMETAS and Astellas Enter into Strategic Partnership on Immuno-oncology

The partnership comprises utilizing MIMETAS’ comprehensive tumor models to support the next generation of immuno-oncological therapies.

Read the full article here

News Article
'
First Large-scale Phenotypic Screen Using Organ-on-a-Chip

Leveraging a 3D angiogenesis assay, MIMETAS executed a 1537 kinase inhibitor library screen.


Read the article

Cookies

May we use cookies?
Hi there! Thanks for visiting our website. We use cookies to keep track of our website statistics to optimize the user experience. We also use cookies for marketing purposes. You can set your preferences by selecting the options below. Terms of Use & Privacy Policy
Accept all
Accept selected
Decline all